Carlsmed Inc (NASDAQ:CARL), a medical technology company focused on AI-enabled personalized spine surgery, reported financial results for the fourth quarter and full year ended December 31, 2025. The company's latest earnings release highlights a period of significant revenue growth, though losses widened as it continues to invest heavily in scaling its commercial and research operations. The market's initial reaction appears cautiously optimistic, with the stock trading higher in after-hours activity following the report.
Earnings and Revenue Versus Estimates
The core of any earnings report lies in the comparison between a company's actual performance and the expectations set by Wall Street analysts. For its fourth quarter, Carlsmed delivered a clear top-line beat while its bottom-line loss was narrower than anticipated.
- Revenue: The company reported Q4 revenue of $15.2 million, surpassing the analyst consensus estimate of approximately $14.8 million. This represents a substantial year-over-year increase of 61.2%.
- Earnings Per Share (EPS): Carlsmed reported a non-GAAP net loss per share of ($0.32). This performance was better than the estimated loss of ($0.43) projected by analysts.
For the full year 2025, revenue reached $50.5 million, an 86% increase over 2024. The annual net loss was ($29.6) million, or ($2.12) per share.
Market Reaction and Price Action
The immediate market response to an earnings beat is often reflected in after-hours trading. Following the release, Carlsmed's stock saw an increase of approximately 3.9%. This positive movement suggests investors were encouraged by the company's ability to exceed revenue expectations and deliver a smaller-than-anticipated quarterly loss. This after-hours gain stands in contrast to the stock's performance over the past month, which had seen a decline of roughly 6.7%.
Key Highlights from the Earnings Report
Beyond the headline numbers, Carlsmed's press release emphasized several operational and clinical milestones that underpin its growth narrative:
- Strong Gross Margin Expansion: The company achieved a gross margin of 76.5% for Q4 2025, up from 74.7% in the prior-year period, indicating improved efficiency in its manufacturing and delivery processes.
- Strategic Business Highlights: Recent achievements include the launch of its aprevo® cervical system, the publication of positive two-year clinical data showing a 74% reduction in revision rates for lumbar patients, and the completion of first-in-human procedures for new surgical applications.
- Increased Operating Investment: Operating expenses rose to $20.9 million in Q4, up from $11.7 million a year ago. This increase was driven by significant investments in sales and marketing ($10.8 million) and research and development ($5.3 million), reflecting a strategic push to capture market share and advance its technology pipeline.
- Robust Balance Sheet: The company ended the year with a strong liquidity position, holding $109.9 million in cash, cash equivalents, restricted cash, and short-term investments.
Forward-Looking Guidance and Analyst Expectations
Management provided financial guidance for 2026, projecting revenue in the range of $70 to $75 million. At the midpoint, this represents year-over-year growth of approximately 44%. This outlook can be compared to the existing analyst consensus, which estimated 2026 sales at roughly $71.7 million. Carlsmed's guidance range brackets the current consensus, aligning closely with Wall Street's expectations for continued robust growth in the coming year.
For a detailed breakdown of future quarterly estimates and historical earnings performance, you can review more data on Carlsmed's earnings and estimates page.
Conclusion
Carlsmed's fourth-quarter results paint a picture of a company successfully executing on its growth strategy. Beating both revenue and earnings estimates, while simultaneously publishing compelling clinical data and launching new products, provides a solid foundation for investor confidence as evidenced by the positive after-hours trading. The company's 2026 revenue guidance reaffirms its commitment to rapid expansion. However, investors will continue to monitor the balance between this top-line growth and the corresponding increase in operating losses, as Carlsmed invests heavily to scale its commercial footprint and technology platform in the competitive spine surgery market.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.